Fierce Biotech

Genentech shreds RIPK1 inhibitor from pipeline after early ph. 2 failure

Published

3 weeks ago

on

Genentech has elected to stop a phase 2 trial of a RIPK1 inhibitor early and dump the asset after an analysis revealed the candidate was unlikely to meet the study’s primary endpoint.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version